[주총 포커스] HLB 주총 현장, 새로 등장한 펜스·사라진 주주 관심

HLB Group's appointment of Samsung BioLogics' former CEO signals a strategic pivot toward becoming a global CDMO player, positioning the company to scale manufacturing if its liver cancer drug ribocertinib wins FDA approval. The company's record health supplements business demonstrates successful diversification beyond single-drug dependency. However, the increasingly restricted shareholder meetings and 37% stock price decline over the past year suggest investor concerns about execution and governance challenges.